IGM Biosciences Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase A...
September 20 2019 - 4:05PM
IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the closing of
its initial public offering of 12,578,125 shares of its common
stock at a price to the public of $16.00 per share, which includes
the exercise in full by the underwriters of their option to
purchase up to 1,640,625 additional shares. The shares began
trading on The Nasdaq Global Select Market on September 18, 2019
under the symbol “IGMS.” IGM received gross proceeds, before
deducting underwriting discounts and commissions and estimated
offering expenses, of approximately $201.3 million.
Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted
as joint book-running managers for the offering.
A registration statement relating to the offering was declared
effective by the United States Securities and Exchange Commission
on September 17, 2019. The offering was made only by means of a
prospectus. A copy of the final prospectus relating to this
offering may be obtained from: Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, by telephone at (877) 821-7388, or by email at
Prospectus_Department@Jefferies.com; Piper Jaffray & Co,
Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email
at prospectus@pjc.com; Stifel, Nicolaus & Company,
Incorporated, Attention: Syndicate, One Montgomery Street, Suite
3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by
email at syndprospectus@stifel.com; or Guggenheim Securities, LLC,
Attention: Equity Syndicate Department, 330 Madison, 8th Floor, New
York, NY 10017, by telephone at (212) 518-9658 or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor will there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful before registration or
qualification under the securities laws of that state or
jurisdiction.
About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a
biotechnology company focused on creating and developing engineered
IgM antibodies for the treatment of cancer patients. Since 2010,
IGM Biosciences has worked to overcome the manufacturing and
protein engineering hurdles that have limited the therapeutic use
of IgM antibodies. Through its efforts, IGM Biosciences has created
a proprietary IgM technology platform for the development of IgM
antibodies for those clinical indications where their inherent
properties may provide advantages as compared to IgG
antibodies.
CONTACT:
Argot Partners David Pitts 212-600-1902
igmbio@argotpartners.com
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From Aug 2024 to Sep 2024
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From Sep 2023 to Sep 2024